DIPEXIUM PHARMACEUTICALS, INC., is a biopharmaceutical company. The Company is focused on the development and commercialization of Locilex. Locilex is a chemically synthesized, 22-amino acid peptide isolated from the skin of the African Clawed Frog. Its mechanism of action kills microbial targets through disruption of bacterial cell membrane permeability. Locilex is also considered a product candidate, to treat mild or moderate acute bacterial skin and skin structure infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). Locilex is initially being targeted for the treatment of mild infections of diabetic foot ulcers (Mild DFI). As of September, 30, 2014, the Company had not generated any revenues.